|
gptkbp:instanceOf
|
gptkb:drug
gptkb:monoclonal_antibody
|
|
gptkbp:administeredBy
|
gptkb:physician
|
|
gptkbp:approvalYear
|
2003
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
gptkb:R03DX05
|
|
gptkbp:brand
|
gptkb:Xolair
|
|
gptkbp:CASNumber
|
gptkb:242138-07-4
|
|
gptkbp:contraindication
|
hypersensitivity to omalizumab
|
|
gptkbp:developedBy
|
gptkb:Genentech
gptkb:Novartis
|
|
gptkbp:firstApprovedCountry
|
gptkb:United_States
|
|
gptkbp:form
|
solution for injection
|
|
gptkbp:halfLife
|
~26 days
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
omalizumab
|
|
gptkbp:indication
|
gptkb:chronic_idiopathic_urticaria
nasal polyps
moderate to severe persistent allergic asthma
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
binds to IgE
inhibits IgE binding to FcεRI receptor
|
|
gptkbp:molecularWeight
|
~149 kDa
|
|
gptkbp:monitoredParameter
|
serum IgE levels
|
|
gptkbp:patent
|
gptkb:Genentech
gptkb:Novartis
|
|
gptkbp:pregnancyCategory
|
B (US)
|
|
gptkbp:PubChem_CID
|
DB00082
|
|
gptkbp:routeOfAdministration
|
subcutaneous injection
|
|
gptkbp:sideEffect
|
headache
injection site reaction
anaphylaxis
|
|
gptkbp:storage
|
2–8°C
|
|
gptkbp:target
|
gptkb:immunoglobulin_E_(IgE)
|
|
gptkbp:UNII
|
4X1U4MP6BR
|
|
gptkbp:usedFor
|
gptkb:chronic_spontaneous_urticaria
asthma
nasal polyps
|
|
gptkbp:bfsParent
|
gptkb:Xolair
|
|
gptkbp:bfsLayer
|
5
|